These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 30166017)

  • 1. Remarkable Long-Term Efficacy of Nivolumab Immunotherapy in a Chinese Patient with Extensive-Disease Small Cell Lung Cancer.
    Jin B; Chuang X; Liu Y
    J Thorac Oncol; 2018 Sep; 13(9):e174-e177. PubMed ID: 30166017
    [No Abstract]   [Full Text] [Related]  

  • 2. Overcoming acquired resistance to PD-1 inhibitor with the addition of metformin in small cell lung cancer (SCLC).
    Kim Y; Vagia E; Viveiros P; Kang CY; Lee JY; Gim G; Cho S; Choi H; Kim L; Park I; Choi J; Chae YK
    Cancer Immunol Immunother; 2021 Apr; 70(4):961-965. PubMed ID: 33084943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extensive-Stage Small-Cell Lung Cancer With Sustained Complete Response to Single-Agent Nivolumab and Immune-Related Dermatitis.
    Widick P; Gill RR; Mantia C; Costa DB; Rangachari D
    Clin Lung Cancer; 2020 Jan; 21(1):e6-e9. PubMed ID: 31640925
    [No Abstract]   [Full Text] [Related]  

  • 4. Use of Immunotherapy in Extensive-Stage Small Cell Lung Cancer.
    Konala VM; Madhira BR; Ashraf S; Graziano S
    Oncology; 2020; 98(11):749-754. PubMed ID: 32663833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nivolumab for the treatment of small cell lung cancer.
    Simeone E; Grimaldi AM; Festino L; Trojaniello C; Vitale MG; Vanella V; Curvietto M; Ascierto PA
    Expert Rev Respir Med; 2020 Jan; 14(1):5-13. PubMed ID: 31622114
    [No Abstract]   [Full Text] [Related]  

  • 6. Immune checkpoint blockade in small cell lung cancer.
    Tay RY; Heigener D; Reck M; Califano R
    Lung Cancer; 2019 Nov; 137():31-37. PubMed ID: 31525648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Indirect comparison of nivolumab ± ipilimumab (CheckMate 032) versus other treatments for recurrent small-cell lung cancer.
    Cope S; Keeping ST; Goldgrub R; Ayers D; Jansen JP; Penrod JR; Korytowsky B; Juarez-Garcia A; Yuan Y
    J Comp Eff Res; 2019 Jul; 8(10):733-751. PubMed ID: 31237143
    [No Abstract]   [Full Text] [Related]  

  • 8. Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032.
    Ready N; Farago AF; de Braud F; Atmaca A; Hellmann MD; Schneider JG; Spigel DR; Moreno V; Chau I; Hann CL; Eder JP; Steele NL; Pieters A; Fairchild J; Antonia SJ
    J Thorac Oncol; 2019 Feb; 14(2):237-244. PubMed ID: 30316010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged Disease Control on Nivolumab for Primary Pulmonary NUT Carcinoma.
    Davis A; Mahar A; Wong K; Barnet M; Kao S
    Clin Lung Cancer; 2021 Sep; 22(5):e665-e667. PubMed ID: 33349572
    [No Abstract]   [Full Text] [Related]  

  • 10. [Immuno-checkpoint inhibitor resistance and strategy in lung cancer].
    Jiang WR; Fang LP; Chang N; Zhang J
    Zhonghua Jie He He Hu Xi Za Zhi; 2020 Jul; 43(7):603-606. PubMed ID: 32629564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.
    Ricciuti B; Genova C; De Giglio A; Bassanelli M; Dal Bello MG; Metro G; Brambilla M; Baglivo S; Grossi F; Chiari R
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):479-485. PubMed ID: 30506406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nivolumab-induced Limbic Encephalitis with Anti-Hu Antibody in a Patient With Advanced Pleomorphic Carcinoma of the Lung.
    Matsuoka H; Kimura H; Koba H; Tambo Y; Ohkura N; Hara J; Sone T; Kasahara K
    Clin Lung Cancer; 2018 Sep; 19(5):e597-e599. PubMed ID: 29857970
    [No Abstract]   [Full Text] [Related]  

  • 13. The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti-Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC.
    Jin Y; Dong H; Xia L; Yang Y; Zhu Y; Shen Y; Zheng H; Yao C; Wang Y; Lu S
    J Thorac Oncol; 2019 Aug; 14(8):1378-1389. PubMed ID: 31026576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic Therapy of Extensive Stage Small Cell Lung Cancer in the Era of Immunotherapy.
    Ragavan M; Das M
    Curr Treat Options Oncol; 2020 Jun; 21(8):64. PubMed ID: 32601742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nivolumab improves survival for patients with advanced lung cancer.
    Printz C
    Cancer; 2017 Sep; 123(17):3211. PubMed ID: 28833027
    [No Abstract]   [Full Text] [Related]  

  • 16. Model-Based Population Pharmacokinetic Analysis of Nivolumab in Chinese Patients With Previously Treated Advanced Solid Tumors, Including Non-Small Cell Lung Cancer.
    Zhang J; Cai J; Bello A; Roy A; Sheng J
    J Clin Pharmacol; 2019 Oct; 59(10):1415-1424. PubMed ID: 31115908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ASO Author Reflections: High Stromal TGFBI is a Useful Predictive Marker for Nivolumab in Non-small Cell Lung Cancer.
    Nakazawa N; Yokobori T; Turtoi A; Shirabe K
    Ann Surg Oncol; 2020 Mar; 27(3):943-944. PubMed ID: 31696394
    [No Abstract]   [Full Text] [Related]  

  • 18. Immune Checkpoint Inhibitors in Small Cell Lung Cancer: A Partially Realized Potential.
    Armstrong SA; Liu SV
    Adv Ther; 2019 Aug; 36(8):1826-1832. PubMed ID: 31209697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical conundrum of managing relapsed small cell lung cancer.
    Nazha B; Owonikoko TK
    Cancer; 2019 Apr; 125(7):1022-1026. PubMed ID: 30561759
    [No Abstract]   [Full Text] [Related]  

  • 20. Nivolumab (Opdivo°) and metastatic or inoperable lung cancer.
    Prescrire Int; 2017 Apr; 26(181):93-94. PubMed ID: 30730658
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.